Bioventus Financial Ratios
NASDAQ: BVSHealth CareMedical/Dental InstrumentsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Bioventus ratio analysis
Bioventus earned a net margin of 4.0% in FY 2025, up from -6.3% a year earlier. Gross margin was 68.3% compared with a median of 69.0% over the prior 6 years. Return on equity reached 12.3%, meaning Bioventus generated 0.12 dollars of profit for every dollar of shareholders' equity.
Debt-to-equity stood at 1.60 versus 2.27 the year before, and the current ratio was 1.70. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Bioventus financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | 21.85 | — | — | — | — | — | — |
| Price / sales | 0.85 | 1.18 | 0.64 | 0.31 | 1.53 | — | — |
| Price / book | 2.61 | 4.56 | 1.90 | 0.49 | 1.44 | — | — |
| Gross margin | 68.3% | 67.7% | 64.1% | 64.6% | 70.3% | 72.7% | 73.3% |
| Operating margin | 9.5% | -2.7% | -16.0% | -32.7% | 2.8% | 6.6% | 9.2% |
| Net margin | 4.0% | -6.3% | -30.5% | -31.0% | 4.5% | 5.1% | 2.0% |
| Free cash flow margin | 12.7% | 6.6% | 1.6% | -2.9% | 2.2% | 17.2% | 11.3% |
| Return on equity (ROE) | 12.3% | -24.4% | -90.0% | -48.8% | 4.2% | — | — |
| Return on assets (ROA) | 3.3% | -5.0% | -19.3% | -11.6% | 1.6% | 3.3% | — |
| Debt / equity | 1.60 | 2.27 | 2.27 | 1.29 | 0.78 | — | — |
| Current ratio | 1.70 | 1.31 | 1.53 | 0.90 | 1.45 | 1.73 | — |
| Revenue growth | -0.9% | 11.9% | 0.0% | 18.8% | 34.2% | -5.6% | — |